Predicting response to benralizumab in patients with COPD: a plain language summary of publication of the GALATHEA and TERRANOVA studies

Abstract

Summary What is this summary about? ● This is a plain language summary of two articles originally published in The New England Journal of Medicine and The Lancet Respiratory Medicine . These articles presented the results of GALATHEA and TERRANOVA, two clinical studies that took place across 41 countries. ○ GALATHEA and TERRANOVA measured how patients’ COPD changed from before their first benralizumab (10, 30, or 100 mg) injection, to after 56 weeks of treatment. ○ In both studies, benralizumab was compared with placebo . ○ To see whether benralizumab treatment would benefit any particular patients included in these studies, researchers carried out an additional analysis following the main studies of GALATHEA and TERRANOVA.